Current concepts in the pathology and genetics of gliomas

Indian Journal of Cancer

Volumn 46, Issue 2, 2009, Pages 108-119

  Sarkar, C ^a   Jain, A ^a   Suri, V ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

1p 19q deletion; Astrocytoma; Glioblastoma; Glioma; Oligodendroglioma

Indexed keywords

ASTROCYTOMA; CANCER GENETICS; CHROMOSOME 19Q; CHROMOSOME 1P; CONFERENCE PAPER; DISEASE SEVERITY; GLIOBLASTOMA; GLIOMA; HUMAN; MOLECULAR BIOLOGY; NEUROPATHOLOGY; OLIGODENDROGLIOMA; PROGNOSIS; TUMOR GROWTH; WORLD HEALTH ORGANIZATION;

ASTROCYTOMA; BRAIN NEOPLASMS; GENE DELETION; GLIOMA; HUMANS; OLIGODENDROGLIOMA; PROGNOSIS;

EID: 64749091382     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.49148     Document Type: Conference Paper

References (167)

1. Zulch KJ. Histological typing of tumors of the central nervous system. Internatinal histological classifcation of tumors, no.21. Geneva: World Health Organization; 1979.
2. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumors of the central nervous system. 2nd ed. International his-tological classifcation of tumors. Berlin, Heidelberg, New York: Springer; 1993.
3. Kleihues P, Cavenee WK. Pathology and genetics of tumors of the nervous system. World Health Organization classifcation of tumors. Lyon: IARC; 2000.
4. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. World Health Organization classifcation of tumors of the central nervous system. Lyon: IARC; 2007.
5. Sanson M, Thillet J, Hoang-Xuan K. Molecular changes in gliomas. Curr Opin Oncol 2004;16:607-13.
6. Reifenberger G, Collins VP. Pathology and molecular genetics of astrocytic gliomas. J Mol Med 2004;82:656-70.
7. Giannini C, Scheithauer BW, Burger PC, Christensen MR, Wollan PC, Sebo TJ, et al. Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol 1999;58:46-53.
8. Sanoudou D, Tingby O, Ferguson-Smith MA, Collins VP, Coleman N. Analysis of pilocytic astrocytoma by comparative genomic hybridization. Br J Cancer 2000;82:1218-22.
9. Kluwe L, Hagel C, Tatagiba M, Thomas S, Stavrou D, Ostertag H, et al. Loss of NF1 alleles distinguish sporadic from NF1 associated pilocytic astrocytomas. J Neuropathol Exp Neurol 2001;60:917-20.
10. Wimmer K, Eckart M, Meyer-Puttlitz B, Fonatsch C, Pietsch T. Mua-tational and expression analysis of the NF1 gene argues against a role as tumor suppressor in sporadic pilocytic astrocytomas. J Neuropathol Exp Neurol 2002;61:1896-902.
11. Ohgaki H, Eibl RH, Schwab M, Reichel MB, Mariani L, Gehring M, et al. Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog 1993;8:74-80.
12. Lang FF, Miller DC, Pisharody S, Koslow M, Newcom EW. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 1994;9:949-54.
13. Hayes VM, Dirven CM, Dam A, Verlind E, Molenaar WM, Mooij JJ, et al. High frequency of TP53 mutations in juvenile pilocytic astrocy-tomas indicates role of TP53 in the development of these tumors. Brain Pathol 1999;9:463-7.
14. Perry A. Pathology of low grade gliomas: An update of emerging concepts. Neuro Oncol 2003;5:168-78.
15. Shafqat S, Hedley-Whyte ET, Henson JW. Age-dependent rate of anaplastic transformation in low-grade astrocytoma. Neurology 1999;52:867-9.
16. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, et al. Prognsotic implications of P53 protien, epidermal growth factor receptor, and Ki-67 labelling in brain tumors. Br J Cancer 1992;66: 373-85.
17. Kleihues P, Davis RL, Ohgaki H, Burger PC, Westphal M, Cavenee WK. Diffuse astrocytoma. In: Kleihues P, Cavenee WK, editors. Pathology and genetics of tumors of the nervous system. World Health Organization classifcation of tumors. Lyon: IARC; 2000.p. 22-6.
18. Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, Collins VP. Deregulation of the p14ARF/Mdm2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 2000;60:417-24.
19. Watanabe K, Peraud A, Gratas C, Wakai S, Kleihues P, Ohgaki H. p53 and PTEN gene mutations in gemistocytic astrocytomas. Acta Neuropathol (Berl) 1998;95:559-64.
20. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, et al. Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992;52:3213-9.
21. Guha A, Dashner K, Black PM, Wagner JA, Stiles CD. Expression of PDGF and PDGF receptors in human astrocytomas operation specimens supports the existence of an autocrine loop. Int J Cancer 1995;60:168-73.
22. Hermanson M, Funa K, Koopmann J, Maintz D, Waha A, Westermark B, et al. Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res 1996;56:164-71.
23. Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen HJ. Prognostic impact of TP53 mutations and p53 protein overexpression in supra-tentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 2002;8:1117-24.
24. Daumas-Duport C, Scheithauer BW, O'Fallon J, Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer 1988;62:2152-65.
25. Perry A, Jenkins RB, O'Fallon JR, Schaefer PL, Kimmel DW, Ma-honey MR, et al. Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors: An analysis of DNA content (ploidy), cellular proliferation, and p53 expression. Cancer 1999;86:672-83.
26. Coons SW, Johnson PC. Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index. J Neuropathol Exp Neurol 1993;52:609-18.
27. Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T. Ki-67 immu-noreactivity in human central nervous system tumors: A study with MIB-1 monoclonal antibody on archival material. Acta Neuropathol 1994;87:47-54.
28. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998;1378:F115-77.
29. Roussel MF. The Ink4 family of cell cycle inhibitors in cancer. On-cogene 1999;18:5311-7.
30. Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS, Collins VP. Amplifcation of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: Preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM 2. Cancer Res 1994;54:4299- 303.
31. Ichimura K, Schmidt EE, Goike HM, Collins VP. Human glioblas-tomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996;13:1065-72.
32. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, et al. PTEN mutation, EGFR amplifcation, and outcome in patients with anaplastic astrocytomas and glioblastoma multiforme. J Natl Cancer Inst 2001;93:1246-56.
33. Wessels PH, Twijnstra A, Kessels AG, Krijne-Kubat B, Theunissen PH, Ummelen MI, et al. Gain of chromosome 7, as detected by in situ hybridization, strongly correlates with shorter survival in astro-cytomas grade 2. Genes Chromosomes Cancer 2002;33:279-84.
34. Kunwar S, Mohapatra G, Bollen A, Lamborn KR, Prados M, Feuerstein BG. Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival. Cancer Res 2001;61:7683-8.
35. Varela M, Ranuncolo SM, Morandi A, Lastiri J, De Kier Joffe EB, Puricelli LI, et al. EGFR and PDGFR, but not bcl-2 overexpression predict overall survival in patients with low grade astrocytomas. J Surg Oncol 2004;86:34-40.
36. Kleihues P, Burger PC, Aldape KD, Brat DJ, Biernat W, Bigner DD, et al. Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. World Health Organization classifcation of tumors of the central nervous system. Lyon: IARC; 2007. p. 33-49.
37. Kraus JA, Lamszus K, Glesmann N, Beck M, Wolter M, Sabel M, et al. Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol 2001;101:311-20.
38. He J, Mokhtari K, Sanson M, Marie Y, Kujas M, Huguet S, et al. Glioblastomas with an oligodendroglial component: A pathological and molecular study. J Neuropathol Exp Neurol 2001;60:863-71.
39. Homma T, Fukushima T, Vaccarella S, Yonekawa Y, Di Patre PL, Franceschi S, et al. Correlation among pathology, genotype, and patient outcomes in glioblastomas. J Neuropathol Exp Neurol 2006;65:846-54.
40. Perry A, Aldape KD, George DH, Burger PC. Small cell astroc-tyoma: An aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendrogliomas. Cancer 2004;101:2318-26.
41. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: From concept to clinical diagnosis. Neuro Oncol 1999;1:44-51.
42. Dropcho EJ, Soong SJ. The prognostic impact of prior low grade histology in patients with anaplastic gliomas: A case-control study. Neurology 1996;47:684-90.
43. Moskowitz SI, Jin T, Prayson RA. Role of MIB1 in predicting survival in patients with glioblastomas. J Neurooncol 2006;76:193-200.
44. Lang FF, Miller DC, Kislow M, Newcomb EW. Pathways leading to glioblastomas multiforme: A molecular analysis of genetic alteration in 65 astroctyic tumors. J Neurosurg 1994;81:427-36.
45. von Deimling A, Louis DN, Wiestler OD. Molecular pathways in the formation of gliomas. Glia 1995;15:328-38.
46. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of EGF receptor and p53 mutation are mutually exclusive in the evolutions of primary and secondary glioblastomas. Brain Pathol 1996;6:216-23.
47. Kliehues P, Ohgaki H. Primary and secondary glioblastomas: From concept to clinical diagnosis. Neuro Oncol 1999;1:44-51.
48. Riemenschneider MJ, Buschges R, Wolter M, Reifenberger J, Bostrom J, Kraus JA, et al. Amplifcation and overexpression of the MDM 4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM 2 amplifcation. Cancer Res 1999;59:6091-6.
49. Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H. Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest 2001;81:77-82.
50. Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H. Loss of heterozygosity on chromosome 19 in secondary glioblas-tomas. J Neuropathol Exp Neurol 2000;59:539-43.
51. Fujisawa H, Reis RM, Nakamura M, Colella S, Yonekawa Y, Kleihues P, et al. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 2000;80:65-72.
52. Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N, et al. Incidence and timing of p53 mutations and during astrocy-tomas progression in patients with multiple biopsies. Clin Cancer Res 1997;3:523-30.
53. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, et al. Genetic pathways to glioblastoma: A population-based study. Cancer Res 2004;64:6892-9.
54. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002;61:321-8.
55. Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL, et al. Survival of patients with glioblastomas multiforme is not infuenced by altered expression of p16, p53, EGFR, MDM 2 or Bcl-2 genes. Brain Pathol 1998;8:655-67.
56. Burton EC, Lamborn KR, Forsyth P, Scott J, O'Campo J, Uyehara-Lock J, et al. Aberracne p53, mdm2, and proliferation differ in glioblasto-mas from long term compared with typical survivors. Clin Cancer Res 2002;8:180-7.
57. Stander M, Peraud A, Leroch B, Kreth FW. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health prganization grade II astrocytoma or oligoastrcotyoma. Cancer 2004;101:1028-35.
58. Hwang SL, Hong YR, Chai CY, Lin HJ, Hwang SL. Prognostic evaluation in supratentorial astrocytic tumors using p53, epidermal growth factor receptor, c-erbB2 immunostaining. Kaohsiung J Med Sci 1998;14:607-15.
59. Rasheed A, Herndon JE, Stenzel TT, Raetz JG, Kendelhardt J, Friedman HS, et al. Molecular markers of prognosis in astrocytic tumors. Cancer 2002;94:2688-97.
60. Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS, et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 2001;61:1122-8.
61. Hurtt MR, Moossy J, Donovan-Peluso M, Locker J. Amplifcation of epidermal growth factor receptor gene in gliomas: Histopathology and prognosis. J Neuropathol Exp Neurol 1992;51:84-90.
62. Torp SH, Helseth E, Dalen A, Unsgaard G. Relationships between Ki-67 labelling index, amplifcation odthe epidermal growth factor receptor gene, and prognosis in human glioblastomas. Acta Neu-rochir (Wein) 1992;117:182-6.
63. Huncharek M, Kupelnick B. Epidermal growth factor receptor gene amplifcation as a prognostic marker in glioblastoma multiforme: Results of a meta-analysis. Oncol Res 2000;12:107-12.
64. Shinojima N, Tada K, Shirishi S, Kamiryo T, Kochi M, Nakamura H, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63:6962-70.
65. Batchelor TT, Betensky RA, Esposito JM, Pham LD, Dorfman MV, Piscatelli N, et al. Age dependent prognostic effects of genetic alteration in glioblastoma. Clin Cancer Res 2004;10:228-33.
66. Burger PC, Pearl DK, Aldape K, Yates AJ, Scheithauer BW, Passe SM, et al. Small cell architecture histological equivalent of EGFR amplifcation in glioblastoma multiforme? J Neuropathol Exp Neurol 2001;60:1099-104.
67. Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic signifcance. J Neuropathol Exp Neurol 2004;63:700-7.
68. Feldkamp MM, Lala P, Lau N, Roncari L, Guha A. Expression of activated epidermal growth factor receptors, Ras-guanosine triphos-phate, and mitogen activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 1999;45:1442-53.
69. Cianciulli AM, Morace E, Coletta AM, Occhipinti E, Gandolfo GM, Leonardo G, et al. Investigation of genetic alteration associated with development and adverse outcome in patients with astrocytic tumor. J Neurooncol 2000;48:9-101.
70. Perry A, Tonk V, McIntire DD, White CL 3rd. Interphase cytoge-netic (in situ hybridization) analysis of astrocytomas using archival, formalin-fxed, paraffn-embedded tissue and nonfuorescent light microscopy. Am J Clin Pathol 1997;108:166-74.
71. Rasheed BK, McLendon RE, Friedman HS, Friedman AH, Fuchs HE, Bigner DD, et al. Chromosome 10 deletion mapping in human gliomas: A common deletion region in 10q25. Oncogene 1995;10:2243-6.
72. Karlbom AE, James CD, Boethius J, Cavenee WK, Collins VP, Nor-denskjold M, et al. Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Hum Genet 1993;92:169-74.
73. Ichimura K, Schmidt EE, Miyakawa A, Goike HM, Collins VP. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer 1998;22:9-15.
74. Burton EC, Lamborn KR, Feuerstein BG, Prados M, Scott J, Forsyth P, et al. Genetic aberrations defned by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res 2002;62:6205-10.
75. Arslantas A, Artan S, Oner U, Muslumanoglu H, Durmaz R, Cosan E, et al. The importance of genomic copy number changes in the prognosis of glioblastoma multiforme. Neurosurg Rev 2004;27:58-64.
76. Schmidt EE, Ichimura K, Goike HM, Moshref A, Liu L, Collins VP. Mu-tational profle of the PTEN gene in primary human astrocytic tumors and cultivated xenografts. J Neuropathol Exp Neurol 1999;58:1170-83.
77. Zhou XP, Li YJ, Hoang-Xuan K, Laurent-Puig P, Mokhtari K, Longy M, et al. Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer 1999;84:150-4.
78. Balesaria S, Brock C, Bower M, Clark J, Nicholson SK, Lewis P, et al. Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas. Br J Cancer 1999;81:1371-7.
79. Fults D, Pedone CA, Thompson GE, Uchiyama CM, Gumpper KL, Iliev D, et al. Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXI1 in human glioblastoma multiforme. Int J Oncol 1998;12:905-10.
80. Backlund LM, Nilsson BR, Goike HM, Schmidt EE, Liu L, Ichimura K, et al. Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clin Cancer Res 2003;9:4151-8.
81. Terada K, Tamiya T, Daido S, Kambara H, Tanaka H, Ono Y, et al. Prognostic value of loss of heterozygosity around three candidate tumor suppressor genes on chromosome 10q in astrocytomas J Neurooncol 2002;58:107-14.
82. Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, et al. Differential expression of MMAC/PTEN in glioblastoma multiforme: Relationship to localization and prognosis. Cancer Res 1999;59:1820-4.
83. Bello MJ, Alonso ME, Amiñoso C, Anselmo NP, Arjona D, Gonzalez-Gomez P, et al. Hypermethylation of the DNA repair gene MGMT: Association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors. Mutat Res 2004;554:23-32.
84. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and beneft from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
85. Kamiryo T, Tada K, Shiraishi S, Shinojima N, Kochi M, Ushio Y. Correlation between promoter hypermethylation of the O6-methylgua-nine- deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery 2004;54:349-57.
86. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C -> A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 2001;22:1715-9.
87. Sarkar C, Karak AK, Nath N, Sharma MC, Mahapatra AK, Chatto-padhyay P, et al. Apoptosis and proliferation: Correlation with p53 in astrocytic tumours. J Neurooncol 2005;73:93-100.
88. Sarkar C, Sinha S, Sharma MC, Kumar R, Mehta VS. Supratentorial glioblastoma in adults: Identifcation of subsets and their clinical correlation. Brain Tumor Pathol 2004;21:7-12.
89. Sharma MC, Ralte AM, Gaekwad S, Santosh V, Shankar SK, Sarkar C. Subependymal giant cell astrocytoma: A clinicopathological study of 23 cases with special emphasis on histogenesis. Pathol Oncol Res 2004;10:219-24.
90. Sarkar C, Ralte AM, Sharma MC, Mehta VS. Recurrent astrocytic tumours: A study of p53 immunoreactivity and malignant progression. Br J Neurosurg 2002;16:335-42.
91. Sarkar C, Rathore A, Chattopadhyaya P, Mahapatra AK, Sinha S. Role of 17p13.3 chromosomal region in determining p53 protein im-munopositivity in human astrocytic tumors. Pathology 2000;32:84-8.
92. Misra A, Chattopadhyay P, Dinda AK, Sarkar C, Mahapatra AK, Has-nain SE, et al. Extensive intra-tumor heterogeneity in primary human glial tumors as a result of locus non-specifc genomic alterations. J Neurooncol 2000;48:1-12.
93. Rathore A, Kamarajan P, Mathur M, Sinha S, Sarkar C. Simultaneous alterations of retinoblastoma and p53 protein expression in astrocytic tumors. Pathol Oncol Res 1999;5:21-7.
94. Ghosh M, Dinda A, Chattopadhyay P, Sarkar C, Bhatia S, Sinha S. Rearranged p53 gene with loss of normal allele in a low-grade nonrecurrent glioma. Cancer Genet Cytogenet 1994;78:68-71.
95. Banerjee M, Dinda AK, Sinha S, Sarkar C, Mathur M. C-MYC oncogene expression and cell proliferation in mixed oligo-astrocytoma. Int J Cancer 1996;65:730-3.
96. Chattopadhyay P, Banerjee M, Sarkar C, Mathur M, Mohapatra AK, Sinha S. Infrequent alteration of the c-myc gene in human glial tumours associated with increased numbers of c-myc positive cells. Oncogene 1995;11:2711-4.
97. Chattopadhyay P, Rathore A, Mathur M, Sarkar C, Mahapatra AK, Sinha S. Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumours. Oncogene 1997;15:871-4.
98. Nayak A, Ralte AM, Sharma MC, Singh VP, Mahapatra AK, Mehta VS, et al. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas. Neurol India 2004;52:228-32.
99. Reifenberger G, Kros JM, Louis DN, Collins VP. Oligodendroglioma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. World Health Organization classifcation of tumors of the central nervous system. Lyon: IARC; 2007. p. 54-9.
100. Ohgaki H, Kleihues P. Population based studies on incidence, survival rates, and genetic alteration in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479-89.
101. Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, et al. Oligodendroglial tumors: refnement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 2004;14:121-30.
102. Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM, Mork S, et al. Oligodendrogliomas: Reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 2001;60:248-62.
103. Lebrun C, Fontaine D, Ramaioli A, Vandenbos F, Chanalet S, Lonjon M, et al. Long-term outcome of oligodendrogliomas. Neurology 2004;62:1783-7.
104. Reifenberger G, Kros JM, Louis DN, Collins VP. Anaplastic Oligo-dendroglioma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. World Health Organization classifcation of tumors of the central nervous system. Lyon: IARC; 2007. p. 60-3.
105. Kros JM, Van Eden CG, Stefanko SZ, Waayer-Van Batenburg M, van der Kwast TH. Prognostic implications of glial fbrillary acidic protein containing cell types in oligodendrogliomas. Cancer 1990;66:1204-12.
106. Reifenberger G, Reifenberger J, Lui L, et al. Molecualr genetics of oligodendroglial tumors. In: Nagai M, editors. Brain Research and Therapy. Tokyo, Japan: Springer-Verlag; 1996. p. 187-209.
107. Reifenberger J, Ring GU, Gies U, Cobbers L, Oberstrass J, An HX, et al. Analysis of p53 mutation and epidermal growth factor receptor amplifcation in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 1996;55:822-31.
108. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145:1175-90.
109. Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997;56:1098-104.
110. Bello MJ, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, Saez-Castresana J, et al. Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int J Cancer 1994;57:172-5.
111. Bello MJ, Leone PE, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, et al. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 1995;64:207-10.
112. Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995;54:91-5.
113. von Deimling A, Louis DN, von Ammon K, Petersen I, Wiestler OD, Seizinger BR. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 1992;52:4277-9.
114. Bigner SH, Rasheed BK, Wiltshire R, McLendon RE. Morphological and molecular genetic aspects of oligodendroglial neoplasms. Neuro Oncol 1999;1:52-60.
115. Jeuken JW, von Deimling A, Wesseling P. Molecular pathogenesis of oligodendroglial tumors. J Neurooncol 2004;70:161-81.
116. Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligoden-drogliomas. Acta Neuropathol 2004;108:49-56.
117. van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, et al. Phase II study of frst-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003;21:2525-8.
118. Kreiger PA, Okada Y, Simon S, Rorke LB, Louis DN, Golden JA. Losses of chromosomes 1p and 19q are rare in pediatric oligodendroglio-mas. Acta Neuropathol 2005;109:387-92.
119. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, et al. Alterations of chromosome arms 1p and 19 q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636-45.
120. Reifenberger G, Louis DN. Oligodendroglioma: Toward molecular defnitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 2003;62:111-26.
121. Fuller CE, Perry A. Molecular diagnostics in central nervous system tumors. Adv Anat Pathol 2005;12:180-94.
122. Griffn CA, Burger P, Morsberger L, Yonescu R, Swierczynski S, Weingart JD, et al. Identifcation of der(1;19)(q10;p10) in fve oligo-dendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006;65:988-94.
123. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66:9852-61.
124. Jaeckle KA, Ballman KV, Rao RD, Jenkins RB, Buckner JC. Current strategies in treatment of oligodendroglioma: Evolution of molecular signatures of response. J Clin Oncol 2006;24:1246-52.
125. Ueki K. Oligodendroglioma: Impact of molecular biology on its defni-tion, diagnosis and management. Neuropathology 2005;25:247-53.
126. Hartmann C, Mueller W, von Deimling A. Pathology and molecular genetics of oligodendroglial tumors. J Mol Med 2004;82:638-55.
127. Kelley TW, Tubbs RR, Prayson RA. Molecular diagnostic techniques for the clinical evaluation of gliomas. Diagn Mol Pathol 2005;14:1-8.
128. Johnson MD, Vnencak-Jones CL, Toms SA, Moots PM, Weil R. Allelic losses in oligodendroglial and oligodendroglioma-like neoplasms: Analysis using microsatellite repeats and polymerase chain reaction. Arch Pathol Lab Med 2003;127:1573-9.
129. Fallon KB, Palmer CA, Roth KA, Nabors LB, Wang W, Carpenter M, et al. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 2004;63:314-22.
130. Buckner JC, Ballman KV, Scheithauer RM. NCCTG 94-72-53: Diagnostic and prognostic signifcance of 1p and 19q deletions in patients with low grade oligodendroglioma and astrocytomas. J Clin Oncol 2005;23:114s.
131. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, et al. Molecular subtypes of anaplastic oligoden-droglioma: Implications for patient management at diagnosis. Clin Cancer Res 2001;7:839-45.
132. Hashimoto N, Murakami M, Takahashi Y, Fujimoto M, Inazawa J, Mineura K. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identifcation of a consistent region of deletion on chromosome arm 1p. Cancer 2003;97:2254-61.
133. Buckner JC, Gesme D Jr, O'Fallon JR, Hammack JE, Stafford S, Brown PD, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: Effcacy and associations with chromosomal abnormalities. J Clin Oncol 2003;21:251-5.
134. Chahlavi A, Kanner A, Peereboom D, Staugaitis SM, Elson P, Barnett G. Impact of chromosome 1p status in response of oligo-dendroglioma to temozolomide: Preliminary results. J Neurooncol 2003;61:267-73.
135. Thiessen B, Maguire JA, McNeil K, Huntsman D, Martin MA, Hors-man D. Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: Relationship to outcome and chemosensitivity. J Neurooncol 2003;64:271-8.
136. van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003;97:1276-84.
137. Cairncross G, Seiferheld W, Shaw E. An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiotherapy (RT) versus RT alone for pure and mixed anaplastic oligodendrolgioma: initial report of RTOG 9402. J Clin Oncol 2004;22:107s.
138. Cairncross G, Seiferheld W, Shaw E. An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiotherapy (RT) versus RT alone for pure and mixed anaplastic oligodendrol-gioma: initial report of RTOG 9402. Presented at the society for Neuro-Oncology 9th Annual Scientifc Meeting, Toronto, Canada, Nov 18-21, 2004.
139. van den Bent MJ, Chinot O, Boogerd W, Bravo Marques J, Taphoorn MJ, Kros JM, et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 2003;14:599-602.
140. Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella-Branger D, et al. Panel review of anaplastic oligodendroglioma from European Organization for Research and Treatment of Cancer Trial 26951: Assessment of consensus in diagnosis, infuence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 2007;66:545-51.
141. Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, et al. Anaplastic Oligodendroglial Tumors: Refning the Correlation among Histopathology, 1p 19q Deletion and Clinical Outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 2008;18:360-9.
142. Aldape K, Burger PC, Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendrogliomas. Arch Pathol Lab Med 2007;131:242-51.
143. Sanson M, Leuraud P, Aguirre-Cruz L, He J, Marie Y, Cartalat-Carel S, et al. Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendrogliomas. J Neurosurg 2002;97:1397-401.
144. Bissola L, Eoli M, Pollo B, Merciai BM, Silvani A, Salsano E, et al. Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. Ann Neurol 2002;52:842-5.
145. Jeuken JW, Sprenger SH, Vermeer H, Kappelle AC, Boerman RH, Wesseling P. Chromosomal imbalances in primary oligodendroglial tumors and their recurrences: Clues about malignant progression detected using comparative genomic hybridization. J Neurosurg 2002;96:559-64.
146. Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, Funada N, et al. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 2002;8:196-201.
147. Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, et al. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998;16:2259-64.
148. Jeuken JW, Nelen MR, Vermeer H, van Staveren WC, Kremer H, van Overbeeke JJ, et al. PTEN mutation analysis in two genetic subtypes of high-grade oligodendroglial tumors: PTEN is only occasionally mutated in one of the two genetic subtypes. Cancer Genet Cytogenet 2000;119:42-7
149. Maier D, Comparone D, Taylor E, Zhang Z, Gratzl O, Van Meir EG, et al. New deletion in low-grade oligodendroglioma at the glio-blastoma suppressor locus on chromosome 10q25-26. Oncogene 1997;15:997-1000.
150. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. PTEN is a target of chromosome 10q loss in anaplastic oligodendro-gliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 2001;159:359-67.
151. Bello MJ, de Campos JM, Vaquero J, Kusak ME, Sarasa JL, Pestaña A, et al. Molecular and cytogenetic analysis of chromosome 9 deletions in 75 malignant gliomas. Genes Chromosomes Cancer 1994;9:33-41.
152. Bigner SH, Matthews MR, Rasheed BK, Wiltshire RN, Friedman HS, Friedman AH, et al. Molecular genetics aspects of oligodendroglio-mas including analysis by comparative genomic hybridization. Am J Pathol 1999;155:375-86.
153. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al. Specifc genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendroglio-mas. J Natl Cancer Inst 1998;90:1473-9.
154. Law ME, Templeton KL, Kitange G, Smith J, Misra A, Feuerstein BG, et al. Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines. Cancer Genet Cytogenet 2005;160:1-14.
155. Bortolotto S, Chiado-Piat L, Cavalla P, Bosone I, Chio A, Mauro A, et al. CDKN2A/p16 inactivation in the prognosis of oligodendroglio-mas. Int J Cancer 2000;88:554-7.
156. Miettinen H, Kononen J, Sallinen P, Alho H, Helen P, Helin H, et al. CDKN2/p16 predicts survival in oligodendrogliomas: Comparison with astrocytomas. J Neurooncol 1999;41:205-11.
157. Alonso ME, Bello MJ, Gonzalez-Gomez P, Arjona D, Lomas J, de Campos JM,
158. Dong SM, Pang JC, Poon WS, Hu J, To KF, Chang AR, et al. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol 2001;60:808-16.
159. von Deimling A, Reifenberger G, Kros JM, Louis DN, Collins VP. Oligoastrocytoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. World Health Organization classifcation of tumors of the central nervous system. Lyon: IARC; 2007. p. 63-7.
160. Shaw EG, Scheithauer BW, O'Fallon JR, Davis DH. Mixed oligoastro-cytomas: A survival and prognostic factor analysis. Neurosurgery 1994;34:577-82.
161. Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002;161:313-9.
162. Beckmann MJ, Prayson RA. A clinicopathologic study of 30 cases of oligoastrocytoma including p53 immunohistochemistry. Pathology 1997;29:159-64.
163. Shimada y, Kubo O, Tajika Y, Hiyama H, Atuji S, Takakura K. Clinico-pathological study of mixed oligoastrocytoma. In: Nagai M, editor. Brain tumor research and therapy. Tokyo: Springer-Verlag; 1997. p. 51-60.
164. Miller CR, Dunham CP, Scheithauer BW, Perry A. Signifcance of necrosis in grading of oligodendroglial neoplasms: A clinicopatho-logic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 2006;24:5419-26.
165. He J, Mokhtari K, Sanson M, Marie Y, Kujas M, Huguet S, et al. Glioblastomas with an oligodendroglial component: A pathological and molecular study. J Neuropathol Exp Neurol 2001;60:863-71.
166. Eoli M, Bissola L, Bruzzone MG, Pollo B, Maccagnano C, De Simone T, et al. Reclassifcation of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer 2006;119:84-90.
167. Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22:3133-8.